1xbet모바일 Pharmaceutical Co., Ltd.

1xbet모바일 Pharmaceutical Co., Ltd. (1xbet모바일) announces that it has decided jointly with Takara Bio Inc, (Takara Bio) to terminate agreements on co-development and exclusive marketing of the drug candidates oncolytic virus HF10 (development code: TBI-1401, INN: canerpaturev） and CD19-targeted CAR gene therapies (development code: TBI-1501).

1xbet모바일 and Takara Bio will continue to co-develop NY-ESO-1・siTCR^TMgene 1xbet모바일rapy product (development code: TBI-1301).

1. 1. Reasons 1xbet모바일 the termination

Oncolytic virus HF10

Both Takara Bio and 1xbet모바일 have discussed development plans for pancreatic cancer and other malignancies after the Phase I clinical trial for pancreatic cancer, however, in consideration of the time required for future development and other factors, two companies have decided to terminate the agreement.

CD19-targeted CAR gene 1xbet모바일rapies

Both companies have been conducting a Phase I/II trial 1xbet모바일 adult acute lymphoblastic leukemia, however, in consideration of the lengthy period 1xbet모바일 clinical development and the competitive landscape, the two companies have decided to terminate the agreement.

2. Details of 1xbet모바일 termination agreement

Under this termination, Takara Bio regains technical, intellectual property and other rights granted by Takara Bio to 1xbet모바일. In addition, in the future Takara Bio will not receive lump-sum payments upon achievement of milestones under this agreement or receive any sales proceeds for clinical trial product sales.

<News releases below on original agreements with Takara Bio

1xbet모바일 Signs Japan-Exclusive License Agreement with Takara Bio for the Investigational Cancer Treatment HF10, an Oncolytic Virus

Otsuka Signs Japan-Exclusive License Agreement

1xbet모바일 enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies

/en/company/newsreleases/2018/20180409_1.html